Zydus receives final approval from the USFDA for Acyclovir Sodium Injection

Deepthi | Myequity news | Date : 05-09-2018 13:00:00 IST

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Sodium Injection, 500 mg (base)/10 mL (50 mg (base)/mL) and 1,000 mg (base)/20mL (50 mg (base)/mL) single-dose vials (USRLD—Zovirax@forinjection). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Acyclovir is an antiviral drug. It slows the growth and spread of the herpes virus in the body. Acyclovir injection is used to treat severe infections caused by herpes viruses, including severe forms of genital herpes, shingles (varicella-zoster), herpes encephalitis (swelling of the brain), neonatal herpes infection and herpes infections in people with other diseases that weaken the immune system.

The group now has 216 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020


More from Myequity